NP-12 (TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. NP-12 (TFA) exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1]. PD-1 signaling pathway[1]
[1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.